NCT07655102

Brief Summary

The goal of this observational study is to evaluate the perioperative risk of malignant ventricular arrhythmias in adult patients diagnosed with Brugada Syndrome undergoing anaesthetic procedures. Brugada Syndrome is a rare inherited cardiac condition associated with an increased risk of life-threatening arrhythmias, and perioperative management remains challenging due to limited high-quality evidence. The main questions it aims to answer are:

  • What is the incidence of malignant ventricular arrhythmias during anaesthesia and up to 30 days after the procedure?
  • Are anaesthetic drugs traditionally considered "non-recommended" associated with an increased risk of perioperative arrhythmic events? Researchers will also explore the relative contribution of anaesthetic drugs versus perioperative physiological factors (e.g., haemodynamic changes, fever, bradycardia) in triggering arrhythmias. Participants will:
  • Undergo anaesthetic procedures (general, locoregional, or sedation) as part of routine clinical care
  • Have clinical data collected prospectively from electronic medical records during the perioperative period
  • Be followed for 30 days after the procedure to assess outcomes, including arrhythmias, complications, ICU admission, and mortality This is a multicentre, prospective observational registry, and no additional interventions or changes to standard clinical practice will be performed.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
29mo left

Started Jul 2026

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 9, 2026

Completed
8 days until next milestone

First Posted

Study publicly available on registry

June 17, 2026

Completed
1 month until next milestone

Study Start

First participant enrolled

July 20, 2026

Expected
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2028

7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 20, 2028

Last Updated

June 17, 2026

Status Verified

April 1, 2026

Enrollment Period

1.9 years

First QC Date

June 9, 2026

Last Update Submit

June 12, 2026

Conditions

Keywords

Brugada SyndromeAnaesthesiaAnesthesiaPerioperative CareVentricular ArrhythmiasCardiac ArrhythmiasPerioperative RiskAnesthetic DrugsPropofolSodium Channel BlockersObservational RegistryMulticentre Study

Outcome Measures

Primary Outcomes (1)

  • Incidence of cardiac arrhytmia from the start of anaesthesia/sedation until 24 hours after the procedure

    To determine the incidence of sustained ventricular tachycardia, ventricular fibrillation, arrhythmic cardiac arrest, aborted sudden cardiac death, or appropriate ICD therapy for ventricular arrhythmia from the start of anaesthesia/sedation until 24 hours after the procedure.

    24 hours

Secondary Outcomes (4)

  • Intraoperative anesthetic management strategies in BrS patients

    During the anesthesic procedure

  • Peri-procedural complications and relevant ECG changes

    During the anesthesic procedure

  • Periprocedural complications

    Perioperative

  • 30 days outcome

    30 days after the anesthesic procedure

Study Arms (1)

Brugada Syndrome Patients Undergoing Anaesthesia

Adult patients (≥18 years) with a confirmed diagnosis of Brugada Syndrome undergoing anaesthetic procedures (general, locoregional, or sedation) for surgical or non-surgical interventions. This is an observational cohort with no assigned interventions. Anaesthetic management, including the use of specific drugs (e.g., propofol, local anaesthetics, ketamine), will be performed according to routine clinical practice. Participants will be followed during the perioperative period and up to 30 days after the procedure to assess the occurrence of malignant ventricular arrhythmias and other clinical outcomes.

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study population will consist of adult patients with a confirmed diagnosis of Brugada Syndrome receiving care at participating tertiary and secondary hospitals. Patients will be identified through preoperative anaesthesia assessments, hospital admissions, and operating room schedules. The registry will include consecutive patients undergoing any type of anaesthetic procedure (general, locoregional, or sedation) for surgical or non-surgical interventions as part of routine clinical care. Participating centres are expected to include institutions with experience in the perioperative management of cardiac patients, ensuring representation of real-world clinical practice across different healthcare settings.

You may qualify if:

  • Documented type 1 Brugada ECG pattern (spontaneous, fever-related, or induced by sodium-channel blocker challenge/other recognised provocation test) with a diagnosis considered compatible with Brugada syndrome by the treating cardiology team.
  • Undergoing general anaesthesia, monitored sedation, loco-regional anaesthesia for any surgical, diagnostic, interventional, obstetric or other non-surgical procedure (including epidural analgesia for labour and sedation for endoscopy).

You may not qualify if:

  • No documented type 1 Brugada ECG pattern, uncertain diagnosis without sufficient supporting data.
  • Refusal to participate in the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital Clinic de Barcelona

Barcelona, Barcelona, 08036, Spain

Location

Related Publications (13)

  • Espinosa A, Ripolles-Melchor J, Brugada R, Campuzano O, Sarquella-Brugada G, Abad-Motos A, Zaballos-Garcia M, Abad-Torrent A, Prieto-Gundin A, Brugada J. Brugada Syndrome: anesthetic considerations and management algorithm. Minerva Anestesiol. 2019 Feb;85(2):173-188. doi: 10.23736/S0375-9393.18.13170-1. Epub 2018 Oct 30.

    PMID: 30394071BACKGROUND
  • Ojaimi RE, Carteron M, Arnold S, Broux N, Corsia G, Zicarelli JP, Benhamou D. Neuraxial anesthesia for delivery in parturtients with Brugada syndrome: Local anesthetics revisited. J Gynecol Obstet Hum Reprod. 2023 May;52(5):102562. doi: 10.1016/j.jogoh.2023.102562. Epub 2023 Feb 27. No abstract available.

    PMID: 36858196BACKGROUND
  • Ripley A, Castro J, Gadsden J. Local anesthetics, neuraxial anesthesia, and the Brugada syndrome. J Clin Anesth. 2013 Feb;25(1):78-9. doi: 10.1016/j.jclinane.2012.06.012. Epub 2012 Dec 12. No abstract available.

    PMID: 23246496BACKGROUND
  • Cole JB, Sattiraju S, Bilden EF, Asinger RW, Bertog SC. Isolated tramadol overdose associated with Brugada ECG pattern. Pacing Clin Electrophysiol. 2012 Aug;35(8):e219-21. doi: 10.1111/j.1540-8159.2010.02924.x. Epub 2010 Oct 7.

    PMID: 21039643BACKGROUND
  • Rollin A, Maury P, Guilbeau-Frugier C, Brugada J. Transient ST elevation after ketamine intoxication: a new cause of acquired brugada ECG pattern. J Cardiovasc Electrophysiol. 2011 Jan;22(1):91-4. doi: 10.1111/j.1540-8167.2010.01766.x.

    PMID: 20384648BACKGROUND
  • Cuttone G, Martucci G, Napoli R, Tigano S, Arcadipane A, Pappalardo F, Sanfilippo F. Anesthesiological management of Brugada syndrome patients: A systematic review. Saudi J Anaesth. 2023 Jul-Sep;17(3):394-400. doi: 10.4103/sja.sja_205_23. Epub 2023 Jun 22.

    PMID: 37601502BACKGROUND
  • Duque M, Santos L, Ribeiro S, Catre D. Anesthesia and Brugada syndrome: a 12-year case series. J Clin Anesth. 2017 Feb;36:168-173. doi: 10.1016/j.jclinane.2016.09.031. Epub 2016 Dec 7.

    PMID: 28183560BACKGROUND
  • Flamee P, Viaene K, Tosi M, Nogueira Carvalho H, de Asmundis C, Forget P, Poelaert J. Propofol for Induction and Maintenance of Anesthesia in Patients With Brugada Syndrome: A Single-Center, 25-Year, Retrospective Cohort Analysis. Anesth Analg. 2021 Jun 1;132(6):1645-1653. doi: 10.1213/ANE.0000000000005540.

    PMID: 33857025BACKGROUND
  • Flamee P, Varnavas V, Dewals W, Carvalho H, Cools W, Bhutia JT, Beckers S, Umbrain V, Verborgh C, Forget P, Chierchia GB, Brugada P, Poelaert J, de Asmundis C. Electrocardiographic Effects of Propofol versus Etomidate in Patients with Brugada Syndrome. Anesthesiology. 2020 Mar;132(3):440-451. doi: 10.1097/ALN.0000000000003030.

    PMID: 31743136BACKGROUND
  • Postema PG, Wolpert C, Amin AS, Probst V, Borggrefe M, Roden DM, Priori SG, Tan HL, Hiraoka M, Brugada J, Wilde AA. Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). Heart Rhythm. 2009 Sep;6(9):1335-41. doi: 10.1016/j.hrthm.2009.07.002. Epub 2009 Jul 8.

    PMID: 19716089BACKGROUND
  • Borrell-Vega J, Fernandez Font JD, Linares M, Martinez-Palli G, Isabel-Roquero A, Mont L, Brugada J, Arbelo E, Gimenez-Mila M. Eighteen-year analysis of anaesthetic management in Brugada syndrome: The BRUGANAES study. Eur J Anaesthesiol. 2025 May 1;42(5):458-467. doi: 10.1097/EJA.0000000000002146. Epub 2025 Feb 12.

    PMID: 39945140BACKGROUND
  • Brugada J, Campuzano O, Arbelo E, Sarquella-Brugada G, Brugada R. Present Status of Brugada Syndrome: JACC State-of-the-Art Review. J Am Coll Cardiol. 2018 Aug 28;72(9):1046-1059. doi: 10.1016/j.jacc.2018.06.037.

    PMID: 30139433BACKGROUND
  • Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol. 1992 Nov 15;20(6):1391-6. doi: 10.1016/0735-1097(92)90253-j.

    PMID: 1309182BACKGROUND

MeSH Terms

Conditions

Brugada SyndromeArrhythmias, Cardiac

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesCardiac Conduction System DiseaseGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
30 Days
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 9, 2026

First Posted

June 17, 2026

Study Start (Estimated)

July 20, 2026

Primary Completion (Estimated)

May 31, 2028

Study Completion (Estimated)

December 20, 2028

Last Updated

June 17, 2026

Record last verified: 2026-04

Locations